Cerebral Amyloid Angiopathy Research Center

Cerebral Amyloid Angiopathy Research Center is a group of Massachusetts General Hospital physician-investigators, scientists, and other research staff. Their research focuses on the development, diagnosis, and treatment of cerebral amyloid angiopathy (CAA). CAA is an important cause of cerebral hemorrhage in the elderly. It is currently one of the few kinds of strokes without effective prevention or treatment strategies.

The research is divided into a clinical program that focuses on the molecular epidemiology of CAA and a laboratory program studying its pathogenesis. Their clinical research program has assembled a cohort of patients with probable CAA-related cerebral hemorrhage.

The goal of their studies is to:

• Identify safe and effective treatments for lowering the risk of recurrent hemorrhage and other forms of clinical deterioration in patients with CAA, such as vascular cognitive impairment.
• Predict a patient’s risk for hemorrhage and thereby allow treatments that affect blood clotting to be used more safely and effectively.